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E-mail address: S.W.Edwards@liv.ac.uk (S.W. EdwaApoptosis, an essential and basic biological phenomenon, is regulated in a complex manner by a
multitude of factors. Myeloid cell leukemia 1 (Mcl-1), an anti-apoptotic member of the B-cell lym-
phoma 2 (Bcl-2) family of apoptosis-regulating proteins, exempliﬁes a number of the mechanisms
by which a protein’s contribution to cell fate may be modiﬁed. The N-terminus of Mcl-1 is unique
amongst the Bcl-2 family, in that it is rich in experimentally conﬁrmed and putative regulatory res-
idues and motifs. These include sites for ubiquitination, cleavage and phosphorylation, which inﬂu-
ence the protein’s stability, localisation, dimerization and function. Here we review what is known
about the regulation of Mcl-1 expression and function, with particular focus on post-translational
modiﬁcations and how phosphorylation interconnects the complex molecular control of Mcl-1 with
cellular state.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The term ‘apoptosis’ was ﬁrst coined by Kerr, Wyllie and Currie
in 1972, when they used live-cell imaging to make detailed obser-
vations of the dynamic behaviour of cells and tissues in culture.
The observed morphological changes were identical in all cells
undergoing apoptosis, which gave rise to the idea that this form
of cell death is genetically programmed in each cell. Apoptosis
has since been identiﬁed as a crucial process, in physiological
terms, for a number of reasons: for the maintenance of tissue
homeostasis, for the safe removal of unwanted or damaged cells,
for morphogenesis during embryonic development, and for the
resolution of inﬂammation. The culmination of apoptosis involves
the activation of a family of cysteine proteases, named caspases,chemical Societies. Published by E
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rds).which are responsible for the dismantling of the cell’s components,
that are then packaged into smaller apoptotic bodies to be cleared
by phagocytes. The activation of caspases is tightly regulated at
multiple levels, and mammalian cells have evolved mechanisms
whereby a cell may intrinsically regulate its own fate, or be extrin-
sically induced to undergo apoptosis. The two pathways share a
number of molecular components, including the B-cell lymphoma
2 (Bcl-2) family – a group of proteins whose role lies in regulating
mitochondrial integrity (Fig. 1). There are now 20 or so known
family members, which are identiﬁed by having sequence homol-
ogy to the eponymous Bcl-2 protein at one or more regions, named
Bcl-2 homology (BH) domains. The family is sub-divided according
to the functional contribution that each protein makes to the pro-
gression of apoptosis, with both pro-survival, and pro-apoptotic
proteins, and it is the balance in activity between these opposing
groups which determines a cell’s progression towards apoptosis.
The current state of knowledge about the Bcl-2 family is reviewed
in detail elsewhere [1,2].
2. Mcl-1 – discovery and characterisation
Mcl-1 (myeloid cell leukemia 1) is a pro-survival member of the
Bcl-2 family that was initially identiﬁed as an immediate-early
gene expressed during PMA-induced differentiation of ML-1 mye-
loid leukemia cells [3]. Alignment algorithms identiﬁed sequence
similarity to the recently discovered pro-survival protein Bcl-2,
and so Mcl-1 constituted only the second of this protein family
when it was discovered. The Bcl-2 family represented a new class
of oncogenes that promoted oncogenesis, not through upregulationlsevier B.V. All rights reserved.
Fig. 1. Interactions of the Bcl-2 family. Bax [1a], a cytosolic protein, and Bak [1b], an integral mitochondrial membrane protein, are retained in monomeric forms by
association with various anti-apoptotic Bcl-2 family members. This repression may be relieved by competitive inhibition from ‘inactivator’ BH3-only proteins, (iBH3) such as
Bad and Noxa. Free cytosolic Bax [2], or free mitochondrial-membrane bound Bak require further association with ‘activator’ BH3-only proteins (aBH3) to induce a
conformational change, and in the case of Bax, for effective mitochondrial targeting. aBH3-only proteins [3] are themselves prevented from associating with Bax and Bak by
inhibitory association with anti-apoptotic Bcl-2 family members such as Mcl-1. As with Bax and Bak, the aBH3-only proteins may be freed by competitive inhibition from
iBH3-only proteins. The conformational change of Bax and Bak [4] permits homo-oligomerisation of the proteins, and the formation of outer-mitochondrial membrane
spanning pores. These Bax and Bak pores permit the release of cytochrome c into the cytoplasm, which triggers activation of the caspase cascade, and ultimately apoptosis.
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apoptosis [4]. As predicted, dysregulation of Bcl-2 protein family
expression and function has since been implicated in virtually all
malignancies, and a number of other pathologies.
Sequence analysis revealed that while Mcl-1 contained 3 puta-
tive BH domains, and experimentally could protect against apopto-
sis, its large N-terminal region contained potential regulatory
motifs that could be predicted to regulate its function (Fig. 2).
Mcl-1 differs from its pro-survival relatives in its larger size of
350 residues, as compared to Bcl-2 at 239 residues (Fig. 2) and
Bcl-2 like protein X (Bcl-XL) at 233 residues. Residues 170–300 of
Mcl-1 share a great deal of structural and functional homology to
both Bcl-2 and Bcl-XL, containing its three BH domains (Bcl-2
and Bcl-X possess 4), which confer the ability to heterodimerize
with other family members [5]. The three solution structures of
Mcl-1 that have been published each use N-terminally truncated
forms of the protein, the ﬁrst study with Mcl-1 as a monomer
[6], the second two studies as dimers with the BH3-domains ofthe pro-apoptotic proteins BH3 interacting domain death agonist
(BID) [7] and p53 upregulated modulator of apoptosis (Puma)
and Noxa [8], respectively. All three studies show that Mcl-1 has
a similar structure to its pro-survival relatives, with a surface-
exposed hydrophobic groove for the binding of other BH3-domain
containing proteins. Mcl-1 blocks the progression of apoptosis by
binding and sequestering the pro-apoptotic proteins Bcl-2 homol-
ogous antagonist killer (Bak) and Bcl-2-associated protein X (Bax),
which are capable of forming pores in the mitochondrial mem-
brane, allowing the release of cytochrome c into the cytoplasm.
In the cytoplasm, cytochrome c induces the activation of a family
of cysteine proteases named caspases which are responsible for
much of the macromolecular degradation observed during apopto-
sis. Mcl-1 also binds and sequesters a subset of the BH3-only
pro-apoptotic Bcl-2 family members, which act to induce the poly-
merisation of Bak and Bax. The repression of Bak and Bax polymer-
isation by Mcl-1 can be relieved both by the degradation of Mcl-1,
and by its interaction with a second subset of the BH3-only
Fig. 2. The molecular organization of Mcl-1. A schematic representation of the Mcl-1 protein, to scale, with the relative positions of the functional regions and sites of post-
translational modiﬁcation highlighted. These include the transmembrane domain (TM), the Bcl-2 homology domains (numbered 1–4), two weak (lower case) and two strong
(upper case) PEST sequences. Sites of post-translational modiﬁcation are also shown, including ubiquitination (Ub), caspase cleavage (Casp), and phosphorylation (Phos). A
schematic of a representative selection of other members of the Bcl-2 family are shown below, to scale, to compare the relative sizes and molecular organization of the
proteins.
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Bak and Bax fromMcl-1. In the C-terminal portion of Mcl-1 there is
also a transmembrane domain, deletion of which blocks membrane
insertion and localisation of the protein [9]. Some clues about the
molecular basis of the functional non-redundancy of the Bcl-2
family were brought to light using these binding studies, which
showed differences in the dimerisation pairs made by the pro-
survival family members. Mcl-1, along with Bcl-2 related protein
A1 constituted a subset which bound strongly to Noxa but only
weakly to Bad, while Bcl-2, Bcl-w and Bcl-XL bound strongly to
Bad, but only weakly to Noxa. Additionally, the BH3-only proteins
Bim and Puma bound promiscuously to all the pro-survival pro-
teins, and Mcl-1 and Bcl-XL have also been shown to preferentially
bind Bak, whereas Bcl-2 does not [7]. The ﬁne details of the Bcl-2
family interactions will continue to be uncovered, but the principal
of partial non-redundancy is clear, and highlights the complexity of
apoptosis regulation in multicellular organisms.
Much less is known about the non-Bcl-2-homologous N-termi-
nal portion of the protein, approximately encompassing residues
1–170, which is predicted to have low-structural complexity, but
is rich in conﬁrmed and putative regulatory motifs. Indeed, since
its discovery, the molecular characteristics of the N-terminus of
Mcl-1 have been under scrutiny, with Kozopas et al. identifying
enrichment of this region with proline (P), glutamic acid (E), serine
(S) and threonine (T) residues, which earned this half of the protein
its name as the ‘proline/glutamic acid/serine/threonine (PEST) re-
gion’ [3]. PEST enrichment and arginine pairs (of which Mcl-1
has four) are common features of labile proteins, and Kozopas
et al. later conﬁrmed this prediction in a study using pulse-chasetechniques [10]. The constitutive half-life of Mcl-1 is the subject
of some uncertainty since the protein’s turnover may be shortened
or lengthened signiﬁcantly depending on the cellular conditions,
and varies between cell types. Factors which inﬂuence the turnover
of Mcl-1 are numerous and varied, and an exhaustive list is beyond
the scope of this review. As expected however, those agents and
conditions which delay Mcl-1 degradation tend to enhance cellular
viability – such as trophic factors – and conversely, agents and con-
ditions which accelerate Mcl-1 degradation act to decrease cellular
viability – such as trophic factor withdrawal, or DNA damage.
3. Mcl-1 – expression and physiological function
Despite an initial appearance of functional redundancy between
individual Bcl-2 family members, differences in both tissue distri-
bution and function have been identiﬁed, and are reviewed else-
where [11]. Mcl-1, like its Bcl-2 relatives, is widely expressed but
has its own particular tissue distribution [10,12] along with its
own speciﬁc physiological roles. Numerous, diverse cell-types have
been shown to be reliant on Mcl-1 for their survival and develop-
ment. For example, Mcl-1 deletion is peri-implantation lethal in
mouse embryogenesis [13], whereas Bcl-2 deletion is not [14].
Mcl-1 has also been shown to be required for the development
and maintenance of B and T-lymphocytes [15], and is also required
for neural development [16]. It has also been shown to play a crit-
ical role in the regulation of macrophage and neutrophil apoptosis
[17,18], and is essential for the survival of haematopoietic stem
cells [19] and synovial ﬁbroblasts [20]. Along with its roles in dif-
ferentiation and apoptosis, Mcl-1 (like its Bcl-2 counterparts [21])
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with cyclin dependent kinase 1 (CDK-1) [22], proliferating cell nu-
clear antigen (PCNA) [23] and checkpoint 1 protein (CHK-1) [24].
Initial studies of Mcl-1 identiﬁed that its expression was
growth-factor dependent in many situations, and that it was capa-
ble of protecting cells from growth factor withdrawal-induced
apoptosis [25]. A growing list of trophic factors have been shown
to induce transcriptional upregulation of Mcl-1, including cyto-
kines such as interleukin (IL)-3 [26], IL-5 [27], IL-6 [28], and gran-
ulocyte–macrophage colony-stimulating factor (GM-CSF) [29], as
well as growth factors such as epidermal growth factor (EGF)
[30] and vascular endothelial growth factor (VEGF) [31]. Intracellu-
lar regulation of Mcl-1 transcription is mediated by a number of
externally activated and constitutively activated transcription fac-
tors, notably the signal transducers and activators of transcription
(STAT) family. The promoter region of Mcl-1, characterised by Ak-
gul et al. [32], contains an array of putative and conﬁrmed tran-
scription factor binding sites, including consensus STAT response
elements, cAMP response elements (CRE), and nuclear factor kappa
B binding sites. Both STAT3, in response to IL-6 [33], VEGF [34] and
IL-3 [26], and STAT5, in response to Bcr–Abl signalling in chronic
myeloid leukemia, have been shown to upregulate Mcl-1 transcrip-
tion. Indeed, it has been suggested that STAT3 activation by phos-
phorylation is absolutely required for Mcl-1 mediated macrophage
survival [35]. Other conﬁrmed transcription factors known to
upregulate Mcl-1 expression include cAMP response element bind-
ing protein [26], PU.1 [36] SP1 [37], and under hypoxic conditions,
hypoxia-inducible factor 1a [38]. Conversely, Mcl-1 may be down-
regulated transcriptionally under a number of conditions, particu-
larly under growth factor withdrawal [29], and on the induction of
apoptosis induced by a variety of treatments, including stauro-
sporine [39] and UV exposure [40]. In most cases, down-regulation
is mediated by inactivation of the transcription factors stimulating
Mcl-1 transcription, but the Mcl-1 promoter is directly repressed
by the binding of the E2F-1 transcription factor (Fig. 3) [41].
In addition to transcriptional regulation, Mcl-1 is also subject to
post-transcriptional and translational control. The mRNA of Mcl-1
can be alternatively spliced to remove exon 2, which produces a
shortened form of Mcl-1, namely Mcl-1S, which lacks BH domains
1, 2 and the transmembrane domain. A second, shorter, splice var-
iant, named Mcl-1ES has also been identiﬁed which lacks a portion
of exon 1, removing 53 amino acids from the PEST region, but re-
tains all three BH domains and the C-terminal transmembrane do-
main [42]. These shortened forms are unable to interact and
sequester the pro-apoptotic Bcl-2 family members, and in fact in-
duce apoptosis by binding and inhibiting full length Mcl-1 [43].
Upregulation of Mcl-1S has been identiﬁed in macrophages during
infection, and this appears to be an important mechanism for the
successful resolution of inﬂammation [44]. The rate of Mcl-1 trans-
lation is also tightly regulated, and Mcl-1 mRNA, like the protein,
has been shown to have a very short half-life. Mcl-1 mRNA trans-
lation is inhibited both by binding of the micro RNA, micro inhib-
iting RNA 29b [45] and the RNA binding protein CUGBP2 [46] at the
30-UTR. Overexpression of either of these inhibitors of Mcl-1 trans-
lation dampens proliferation and induces apoptosis.4. Contribution to pathophysiology
Well-regulated apoptosis is an essential process in develop-
ment, tissue homeostasis and the regulation of inﬂammation, con-
versely dysregulation of apoptosis has wide-ranging inﬂuences in a
number of pathophysiologies [47]. Excessive apoptosis is impli-
cated in a number of neurodegenerative diseases such as Alzhei-
mer’s [48] and multiple sclerosis [49], while evasion of apoptosis
is a cardinal step in oncogenesis [50] and many inﬂammatoryconditions [47]. Mcl-1 overexpression has been reported in several
haematological cancers [51–53] and solid tumours [54–56],
including chronic myeloid leukemia and hepatocellular carcinoma.
It has also been implicated in the chemoresistance of certain
malignancies [56–58], notably against the ﬁrst of a new class of
Bcl-2 family targeting compounds, named ABT-737 [59]. Forced
overexpression of Mcl-1 in transgenic mice led to a signiﬁcantly in-
creased incidence of B-cell lymphoma [60], while forced Mcl-1
down-regulation is able to induce apoptosis in a number of cancer
cell types [61]. Thus Mcl-1 is an attractive and potential therapeu-
tic target in a number of malignancies, and is the focus of a number
of studies (reviewed in [62]).5. Molecular characteristics
As described above, Mcl-1 has a unique tissue expression and
specialised roles in physiology and pathology that set it apart from
other Bcl-2 family members. It appears that many of these unique
properties are determined by the large N-terminal domain of Mcl-
1, which contains manymotifs that affect its rate of turnover, local-
isation and phosphorylation status. These post-translational mod-
iﬁcations of Mcl-1 provide the protein with the ability to rapidly
and reversibly respond to environmental signals, and switch cell
fate from survival to apoptosis.
5.1. Degradation
The degradation of Mcl-1 was ﬁrst attributed to the proteasome
by Nijhawan et al. in HeLa cells exposed to UV irradiation [40], and
later conﬁrmed by our own group and others [63]. The lysine res-
idues targetted for ubiquitination (Fig. 2) were then identiﬁed and
characterised by Zhong et al., who also discovered a novel E3 ubiq-
uitin-ligase responsible for the constitutive polyubiquitination of
Mcl-1, which they named Mcl-1 Ubiquitin Ligase E3 (MULE) [64].
However Mcl-1 degradation during apoptosis may be further
accelerated, both by activation of other ubiquitin ligases and cleav-
age by other proteases. A second E3-ligase which targets Mcl-1 has
been identiﬁed by Ding et al., namely beta transducin-containing
protein (b-TrCP), which polyubiquitinates and targets Mcl-1 for
degradation following GSK-3 phosphorylation of Mcl-1 (discussed
in greater detail later) [65]. Conversely, Mcl-1 has also recently
been shown to be the target of a deubiquitinase, named USP9X,
which stabilizes Mcl-1 by reversing its polyubiquitination [66].
Secondly, it was known that Mcl-1 was additionally subject to
non-proteasomal degradation, particularly during the progression
of apoptosis, and two groups simultaneously characterised the cas-
pase-dependent cleavage of Mcl-1 at two distinct sites within the
N-terminus (Fig. 2) [67,68]. Han et al. then identiﬁed Granzyme
B (GrB) cleavage of Mcl-1 at the same two sites (and one other)
during GrB-mediated apoptosis [69]. Cleavage of Mcl-1 at these
sites unambiguously impairs the protein’s ability to protect against
apoptosis by inhibiting dimerisation with its cognate pro-apoptotic
partners. However, some studies have reported that cleavage at
these sites additionally converts Mcl-1 to a pro-apoptotic protein
[67,70], although this has been disputed by others [68,71]. Never-
theless, it is clear that cleavage of Mcl-1 is an important process by
which the contribution of Mcl-1 to cell viability may be rapidly
regulated.
5.2. Localisation
Under resting conditions, Mcl-1 is localised to various cellular
membranes, including the mitochondria [9,10] and nuclear enve-
lope [72], but it also has prominent cytosolic localisation, presum-
ably as a heterodimer with Bax, and in some studies has been
Fig. 3. Overview of the molecular regulation of Mcl-1 [1]. Trophic signalling by cytokines and growth factors activates a number of transcription factors which stimulate Mcl-
1 transcription, which can be repressed by the E2F-1 transcription factor [2]. Alternative splicing leads to the production of three mRNA species: full length (mcl-1L), short
(mcl-1S) and extra short (mcl-1ES). The latter two are unable to bind and sequester pro-apoptotic Bcl-2 family members, and instead bind and inactivate full length Mcl-1 [3].
Translation of full length Mcl-1 mRNA is negatively regulated by both the microRNA Mir-29b and the RNA binding protein CUGBP2 [4]. Pro-apoptotic extracellular signalling
leads to the activation of caspase-8 which cleaves and activates Bid which binds and inhibits Mcl-1 [5]. Additionally, paracellularly secreted Granzyme B cleaves and
inactivates Mcl-1 [6]. Mcl-1 is subject to constitutive degradation by the proteasome, and this may be accelerated or inhibited by phosphorylation at various residues,
described in detail in later sections [7]. On the induction of apoptosis, the cascade of caspase activation is ampliﬁed by caspase-3 mediated cleavage and inactivation of Mcl-1.
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the mitochondria has been shown to be dependent on both the ﬁrst
79 residues of Mcl-1 [73], an internal EELD sequence (at residue
124–127), interaction with the Tom70 receptors [74] and the C-
terminal transmembrane domain [9]. Indeed, the ability of Mcl-1
to localise to the mitochondria is necessary for it to counter the
activity of the pro-apoptotic proteins Bak and Bax [73]. Nuclear
localisation of Mcl-1 has been attributed to interactions with
CDK-1 and PCNA, though the molecular regulation of these interac-
tions and transport of Mcl-1 across the nuclear membrane is, as
yet, unknown.
5.3. Phosphorylation
In the preceding part of this review, we have detailed the major-
ity of mechanisms by which the function of Mcl-1 is regulated, and
these mechanisms are themselves regulated by the phosphoryla-
tion of Mcl-1. Phosphorylation is an almost universal, rapid andreversible modiﬁcation of proteins that has wide-ranging inﬂu-
ences on protein behaviour, including protein localisation, struc-
ture, protein–protein interactions, stability, the regulation of
other protein modiﬁcations and protein function. Thus, phosphor-
ylation serves to integrate a complex array of biological processes
that may be complimentary, or in opposition to each other. The
PEST region of Mcl-1 is rich in putative phosphorylation sites,
and a number of these have been experimentally conﬁrmed, and
their inﬂuence on Mcl-1 behaviour have, in part, been elucidated.
In the ﬁnal part of this review, we detail those phosphoresidues
of Mcl-1 that have been conﬁrmed experimentally as well as
describing their inﬂuence on Mcl-1 function (Figs. 4 and 5).
5.3.1. Serine 64
This phosphoresidue was identiﬁed and conﬁrmed in vivo by
Kobayashi et al. [75] using mass spectrometric analysis of a threo-
nine 163 to alanine (T163A) mutant of Mcl-1. The residue was
found to be phosphorylated by CDKs 1 and 2, and by C-Jun N-ter-
Fig. 4. Signalling pathways and Mcl-1 phosphorylation. A schematic diagram representing the conﬁrmed signalling pathways and kinases that leads to the phosphorylation
of Mcl-1. The inﬂuence that phosphorylation of each residue has on the stability of Mcl-1 (left panel) and the progression of apoptosis (right panel) is also shown, whether
positively (+) or negatively () or if this is currently unknown (?).
Fig. 5. The phosphoresidues of Mcl-1. A schematic diagram of the Mcl-1 protein, to scale, summarising the experimentally conﬁrmed phosphoresidues of Mcl-1, and the
inﬂuence that each phosphorylation has on protein stability, dimerization and function.
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the G2/M phase of the cell-cycle than at the G1/S boundary, sug-
gesting that there is a cell cycle-dependency for Ser64 phosphory-
lation. No signiﬁcant differences in protein stability were found
between wild-type Mcl-1 and phosphonegative (S64A) or phos-
phomimic (S64E) forms, suggesting that this residue does not
inﬂuence the rate of Mcl-1 turnover. It was demonstrated that
the S64A mutant of Mcl-1 had lower binding afﬁnity for various
pro-apoptotic members of the Bcl-2 family compared to the S64E
phosphomimic mutant, and that this translated to a decreased
ability to counter TRAIL-induced apoptosis.5.3.2. Threonine 92
This phosphoresidue was identiﬁed by Ding et al. [76] using an
in vitro extracellular regulated protein kinase-1 (ERK-1) kinase as-
say, with puriﬁed GST-tagged Mcl-1 as the substrate, followed by
mass spectrometric analysis, and both Thr92 and Thr163 were found
to be simultaneously phosphorylated. It was found that a double
T92/163A phosphonegative mutant of Mcl-1 was signiﬁcantly less
stable than the wild-type, and a double T92/163D phosphomimic
mutant was signiﬁcantly more stable. The authors then discovered
that siRNA knockdown of the peptidyl-prolyl cis/trans isomerase,
peptidyl-prolyl cis–trans isomerase NIMA interacting protein 1
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activation, which suggests that Erk-1 phosphorylation of these res-
idues stabilizes Mcl-1 by promoting association with Pin-1. No di-
rect assessment of the anti-apoptotic function of Thr92
phosphomutants was made, only inferentially using Pin1 siRNA
knock-down, which led to a small increase in constitutive apopto-
sis, but also strongly sensitized the cells to Taxol and 5-ﬂuorouracil
induced apoptosis.
5.3.3. Serine 121
This phosphoresidue was identiﬁed by Inoshita et al. [77] in a
study investigating the inﬂuence of oxidative stress on apoptosis,
and also by Kodama et al. [78]. Inoshita et al. identiﬁed that
phosphonegative mutation at Ser121 and Thr163 abrogated the
phosphorylation-dependent electrophoretic mobility shift of Mcl-
1, induced by H2O2 treatment. Similarly, Kodama et al. discovered
that the same phosphonegative mutation abrogated Ser/Thr phos-
phorylation of Mcl-1 in primary mouse hepatocytes. JNK was iden-
tiﬁed in both studies as the kinase responsible for phosphorylation
at this residue. While Inoshita et al. did not detect any changes in
Mcl-1 stability when Ser121 (in conjunction with Thr163) was mu-
tated, Kodama et al. found that in their model, a double S121A/
T163A mutant of Mcl-1 was signiﬁcantly less stable than the
wild-type. Kodama et al. concluded that JNK phosphorylation of
Mcl-1 at Ser121, in conjunction with Thr163, stabilizes Mcl-1 and
affords protection against TNFa-induced apoptosis. However,
Inoshita et al. demonstrated in their study that a double phospho-
negative S121A/T163A mutant of Mcl-1 was signiﬁcantly more
potent at inhibiting apoptosis induced by H2O2 treatment.
5.3.4. Serine 155
This phosphoresidue was identiﬁed by Ding et al. [65] in a study
investigating the role of Glycogen Synthase Kinase (GSK) 3 in tu-
mour apoptosis. Initially, they identiﬁed that GSK-3 inhibition,
through either mutation or chemical means, led to an increase in
Mcl-1 expression whereas expression of constitutively active
GSK-3 decreased Mcl-1 expression. Using sequence analysis, the
authors then identiﬁed two potential consensus GSK-3b phosphor-
ylation motifs (150SGGNN154T and 155STDG159SLPS163T), but only
phosphonegative mutation of the second, named Mcl-1-3A, abol-
ished GSK-3bmediated phosphorylation in an in vitro kinase assay.
Phosphorylation at Ser155 was then conﬁrmed using phospho-spe-
ciﬁc antibodies (to Ser155, Ser159 and Thr163), and it was found that
GSK-3b phosphorylated all three residues in the sequence, while
under the same conditions ERK-1 phosphorylated only Thr163.
The authors also found that phosphonegative mutation of Ser155
(in conjunction with Ser159 and Thr163) in the Mcl-1-3A mutant,
stabilised Mcl-1 compared to the wild-type. Finally, the authors
showed that the Mcl-1-3A mutant of Mcl-1 was signiﬁcantly more
potent at inhibiting the apoptosis of MCF-7 breast cancer cells in-
duced by 5-ﬂuorouracil, cisplatin and taxol, as compared to the
wild-type.
5.3.5. Serine 159
The phosphorylation of serine 159 has been identiﬁed by three
groups, Ding et al. [65] in the work described above, by Maurer et
al. [79], and by Morel et al. [80]. All three studies identiﬁed GSK-3
as the kinase targetting this residue, and discovered that phosphor-
ylation of this residue led to signiﬁcant decrease in Mcl-1 protein
expression. Morel et al. also identiﬁed that an initial ‘priming’
phosphorylation of Thr163 (by JNK) was required for Ser159 phos-
phorylation – a characteristic of other GSK-3 targets [81] – using
sequential in vitro JNK and GSK-3 kinase assays. Both Morel et al.
[80] and Maurer et al. [79] found that phosphonegative mutation
of Ser159 stabilized Mcl-1, following UV-irradiation or cyclohexi-
mide (CHX) treatment respectively. Ding et al. showed that ubiqui-tination of Mcl-1 following Ser159 phosphorylation was mediated
by the E3 ubiquitin ligase b-TrCP, rather than MULE. Finally, Maur-
er et al. and Morel et al. both demonstrated that phosphonegative
mutation of Mcl-1 at Ser159 affords better protection against IL-3
withdrawal-induced apoptosis and UV irradiation-induced apopto-
sis respectively. Maurer et al. additionally showed that in the ab-
sence of IL-3 (in order to initiate apoptosis and a Bim:Mcl-1
interaction), Bim was only co-immunoprecipitated with Mcl-1 fol-
lowing treatment with the small-molecule inhibitor of GSK-3,
CHIR-611. In conclusion, GSK-3 phosphorylation at Ser159 both
destabilizes Mcl-1 and inhibits the interaction of Mcl-1 with the
pro-apoptotic protein, Bim, thus impairing its anti-apoptotic
function.
5.3.6. Threonine 163
This residue was the ﬁrst experimentally conﬁrmed phospho-
residue of Mcl-1, in a study by Inoshita et al. [77], and is also the
most highly investigated, having been conﬁrmed twice by Ding
et al. [65,76] and also by Domina et al. [82]. Inoshita et al. ﬁrst
identiﬁed Thr163 as a strong candidate phosphoresidue from se-
quence analysis, and this was later repeated by Domina et al.,
who noted that the residue lies within a complete consensus
MAP kinase phosphorylation sequence, and is highly conserved
across species. Domina et al. identiﬁed this residue as a target for
ERK-1 in response to TPA stimulation of CHO and BL41-3 cells,
using 32P incorporation assays, as well as utilising inhibitors of
ERK. This observation was later conﬁrmed in a study by Ding
et al. using an in vitro ERK-1 kinase assay [76]. The inﬂuence of sin-
gle Thr163 phosphorylation on Mcl-1 stability was inferred by
Domina et al. from two experiments. Firstly, TPA treatment signif-
icantly increased the stability of endogenous Mcl-1 in BL41-3 cells
following treatment with CHX at 25 lg/mL (88 lM). Secondly,
since mutation of threonine 163 to alanine abolished TPA-induced
phosphorylation of Mcl-1, it was concluded that TPA-induced
phosphorylation of Thr163 stabilizes Mcl-1. It must be noted that
this is seemingly contradicted by the results published by Inoshita
et al. who concluded that phosphorylation of Thr163 by JNK desta-
bilized Mcl-1, though Domina et al. address this and point out that
Inoshita et al. used a double S121A/T163A mutant in their stability
experiments, which confounds any conclusions that may be drawn
about Thr163 phosphorylation alone. While Domina et al. made no
investigation as to the inﬂuence of Thr163 on the anti-apoptotic
function of Mcl-1, other reports have done so, but only in conjunc-
tion with phosphorylation of other residues. Ding et al. inferred in
one report that co-phosphorylation of Thr163 with Thr92 by ERK-1
improves Mcl-1 function [76], and showed in a second that co-
phosphorylation of Thr163 with Ser155 and Ser159 by GSK-3 impairs
its anti-apoptotic function [65]. Inoshita et al. similarly show that
co-phosphorylation of Thr163 with Ser121 ‘inactivates’ Mcl-1, and
impairs its anti-apoptotic function in response to H2O2 treatment
[77].6. Discussion
Evidence is accumulating that Mcl-1 is a protein whose contri-
bution to cell fate is rapidly and acutely regulated, through changes
in transcription, localisation, stability and its ability to form dimers
with Bcl-2 homologues and other proteins. Much of this ﬂexibility
in expression and anti-apoptotic function appears to be due to its
unique (among the Bcl-2 family) and extensive N-terminal portion
which contains a large number of modiﬁable residues, and there-
fore appears to act as a regulatory region. With such complex reg-
ulation of protein function at multiple levels, it is highly likely that
these regulatory processes are context-based. For example, the
regulatory mechanisms that operate in different cells and tissues
2988 L.W. Thomas et al. / FEBS Letters 584 (2010) 2981–2989under varying conditions of stress or other environmental factors
could lead to differential activation of kinase/phosphatase cas-
cades, or alternative proteolytic pathways (e.g. calpains, protea-
some, or caspases). It is also important to bear in mind that some
regulatory mechanisms may be cell-cycle dependent. Thus, while
the range of methodological approaches used to study Mcl-1 func-
tion may sometimes yield conﬂicting data, genuine variance in the
mechanisms of Mcl-1 regulation may exist in cells and tissues un-
der different pathophysiological conditions.
The published data detailed in this review highlights some
important problems when attempting to piece together an
accurate picture of the molecular regulation of Mcl-1 by phosphor-
ylation. The gold-standard technique for conﬁrmation of
phosphorylation at a particular residue is mass-spectrometry.
However, since sample preparation can be complicated, particu-
larly for a low abundance protein such as Mcl-1, most groups
resort to in vitro kinase assays of immunoprecipitated exoge-
nously-expressed tagged forms of the protein. The second choice
for conﬁrmation of phosphorylation is with the use of phospho-
speciﬁc antibodies, which have the added beneﬁt of being usable
for the detection of changes in relative levels of phosphorylation
by immunoblotting. Finally, autoradiographic detection of 32P
incorporation into mutant forms of Mcl-1 is useful and has been
widely used, but suffers from being a less direct and speciﬁc ap-
proach than either mass-spectrometry or phospho-speciﬁc
antibodies.
More difﬁculties arise when comparing the data regarding the
inﬂuence of phosphoresidues on the stability of Mcl-1. None of
the stability experiments detailed here share the same experimen-
tal conditions, with wide variations in the cell-types, molecular
characteristics of the Mcl-1 being assessed, expression systems,
chemical treatments and data analyses used. While transient
transfection of mutant forms of Mcl-1 is widely used and bypasses
the technical challenges of creating stable transfectants, there is of-
ten no control for transfection efﬁciency, and sometimes no means
of distinguishing between exogenously and endogenously ex-
pressed Mcl-1. The use of the translation inhibitor CHX is common,
and yet the quoted working concentrations vary from 5 lg/mL to
5 mg/mL. This variation confounds comparison of the data from
different studies, since there is a concentration-dependent effect
of CHX treatment on the expression of labile proteins, and issues
of cytotoxicity at higher concentrations (>30 lg/mL). In addition,
most studies use doubly or triply mutated forms of Mcl-1, making
it hard to elucidate the contribution of individual residues.
Nevertheless, some principals are clear from the literature.
Firstly that phosphorylation at Thr163 contributes to the stabiliza-
tion and destabilization of Mcl-1 depending on the activity of other
kinases. The literature currently highlights Thr163 as one of, if not
the key phosphoresidue in regulating the fate of Mcl-1, since it ap-
pears to be a necessary ‘priming’ site for phosphorylation of, or at
least to be phosphorylated in conjunction with all other experi-
mentally conﬁrmed phosphoresidues, with the exception of Ser64.
Secondly, phosphorylation by GSK-3 at multiple residues is a key
modiﬁcation for the rapid degradation of Mcl-1. Thirdly that con-
stitutive Erk-1 phosphorylation at Thr163 stabilizes Mcl-1 under
resting conditions. The inﬂuence of JNK phosphorylation is less
clear, since it appears to be required at Thr163 for the destabilizing
phosphorylation of Ser159 and Ser155 by GSK-3, while also itself
phosphorylating and stabilizing Mcl-1 at Ser121. Next, two studies
have identiﬁed that phosphorylation of certain residues affects the
degree of Mcl-1 ubiquitination [65,79], and thus it would appear
that modiﬁcation by phosphorylation leads to exposure or masking
of lysine residues for binding and modiﬁcation by ubiquitin ligases.
And ﬁnally, while the N-terminal portion of the protein is pre-
dicted to have low-structural complexity, it evidently must play
a role in regulating the binding of Mcl-1 to other proteins. Abrogat-ing the phosphorylation of Ser159 diminished the ability of Mcl-1 to
associate with the BH3-only protein Bim, while the same treat-
ment of Thr92 inhibited the association of Mcl-1 with Pin-1. Cur-
rently however, the only published solution structures of Mcl-1
are of N-terminally truncated forms of the protein [6,8], and so
the exact steric behaviour of this portion of Mcl-1 is still unknown,
though this will be of importance in understanding how its modi-
ﬁcation can inﬂuence Mcl-1 dimerization. Phosphorylation must
also play a role in regulating the inﬂuence of Mcl-1 on the cell cycle
– an exciting but underinvestigated feature of the Bcl-2 protein
family. Phosphorylation of Ser64 was found to have a cell-cycle
dependency, and since Mcl-1 has been reported to bind to CDK1,
PCNA and CHK-1 in vivo [22], it is tempting to hypothesise that
phosphorylation of this residue may regulate the timing of these
dimerisations.
These data highlight the multifactorial nature of the regulation
of cell fate, and how proteins such as Mcl-1 intersect opposing and
complimentary signalling cascades, and can effect changes in the
balance between these signals.Acknowledgements
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